Abstract No. 154 Medical crowdfunding for interventional oncology treatments

Abstract

EASL) criteria. Overall radiologic response (ORR) was defined as those who showed a partial or complete response. Survival was measured from the initial radioembolization to time of death and patients were censored for transplant. Patients were separated into cohorts utilizing an ALRI of 100. Results: The average pretreatment ALRI was 99.9 ± 195.3. When comparing those who had an ORR to those who did not the ALRI was not significantly different (93.2 ± 215.7 vs 111.2 ± 156.3, P ¼ 0.28). When looking at those with an ALRI< 100 and 100 there was no significant difference in the OS (1.04 ± 0.99 vs 0.85 ± 0.7 years, P ¼ 0.17). The percentage of patients with ALRI < 100 who had an ORR was 83.7% (77/92) and with those >100 it was 71.9% (23/32) (P ¼ 0.14). Of those patients with both pre and post TACE ALRI values, those that demonstrated a decrease in ALRI did not differ in OS from those who did not have an increase in ALRI (1.02 ± 0.99 vs 1.13 ± 0.64 years, P ¼ 0.39). Similarly, there was no significant difference in the ORR in those who did (68/86, 79.1%) and those who did not (18/22, 81.8%) have an increase in their ALRI following treatment (P ¼ 0.77). Conclusions: ALRI does not appear to have predictive value in HCC patients undergoing treatment with radioembolization, an interesting finding as it departs from its value in patients being treated with other locoregional therapies for the same disease.